Lynk’s zemprocitinib commercial partner, Simcere, will now continue the JAK inhibitor’s development across China in RA.

JAK inhibitors, a new class of tsDMARDs, have shown superior efficacy in RCTs for RA compared to other biologics. Real-world studies highlight JAK inhibitors' benefits in clinical disease activity, ...

In 2023, the groundbreaking Australian BANDIT (Baricitinib in New Onset Type 1 Diabetes) trial reported that a daily pill of baricitinib, commonly prescribed for rheumatoid arthritis and alopecia, ...

People with atopic dermatitis often need to use many different medicines every day to help with their itchiness and rashes. Treatments, like lotions and creams, can be applied directly to the affected ...

JAK inhibitors like baricitinib, ritlecitinib, and brepocitinib show promise in treating alopecia areata, with baricitinib approved by FDA and EMA. Baricitinib significantly reduced SALT scores at 24 ...

A 28-year-old woman presented to her primary care provider with the chief report of persistent itch associated with atopic dermatitis (AD), with itch severity worst on her hands bilaterally. AD was ...

Previous, smaller studies had found that patients tended to gain weight while on the Janus kinase (JAK) inhibitor tofacitinib. This study, funded by tofacitinib's manufacturer, analyzed data from more ...